For the Inventor, By the Inventor

Enter assignee name

Porton Down, United Kingdom

Kalvista Pharmaceuticals Limited

USPTO Granted Patents = 23

% Expired Patents = 39.1

CIPO Patents = 1

EPO Patents = 17

Forward Citations = 99

Loading Chart...

Loading Chart...

38 inventors (with patents filed for the assignee):

Hannah Joy Edwards (16 out of 17 patents)

David Michael Evans (15 out of 25 patents)

Rebecca Louise Davie (13 out of 14 patents)

4. Simon Teanby Hodgson (9 out of 9 patents)

5. David Malcolm Crowe (4 out of 8 patents)

6. David Philip Rooker (4 out of 5 patents)

7. Andrew Richard Novak (3 out of 20 patents)

8. Gary Paul Cook (3 out of 12 patents)

9. Haydn Beaton (3 out of 3 patents)

10. Richard Simon Todd (2 out of 2 patents)

11. Theodore Patrick Laslo (2 out of 2 patents)

12. Premji Meghani (2 out of 40 patents)

13. Stephen John Pethen (2 out of 3 patents)

14. Alun John Smith (2 out of 5 patents)

15. Michael John Stocks (2 out of 2 patents)

23 patents: Sort by Forward Citations

1. 11739068 - Polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof (2023-08-29),

2. 11613527 - Enzyme inhibitors (2023-03-28),

3. 11584735 - Solid forms of a plasma kallikrein inhibitor and salts thereof (2023-02-21),

4. 11242333 - Inhibitors of plasma kallikrein (2022-02-08),

5. 11234939 - Dosage forms comprising a plasma kallikrein inhibitor (2022-02-01),

6. 11230537 - Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors (2022-01-25),

7. 11198691 - N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors (2021-12-14),

8. 11180484 - Pyrazole derivatives as plasma kallikrein inhibitors (2021-11-23),

9. 11084809 - N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors (2021-08-10),

10. 11001578 - N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors (2021-05-11),

11. 10781181 - N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors (2020-09-22),

12. 10752607 - Polymorphs of N-[(6-cyano-2-fluoro)-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide as kallikrein inhibitors (2020-08-25),

13. 10611758 - N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors (2020-04-07),

14. 10478409 - Pharmaceutical compositions (2019-11-19),

15. 10364238 - N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors (2019-07-30),

Company Overview

Kalvista Pharmaceuticals Limited is a biopharmaceutical company based in Porton Down, GB, focused on developing innovative therapies for diseases with significant unmet medical needs. The company specializes in the research and development of small molecule drugs, particularly in the areas of ophthalmology and other therapeutic domains. Kalvista aims to leverage its proprietary technology platform to create effective treatments that enhance patient outcomes and address critical health challenges.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

23 Patents

#1 in Porton Down

#773 in United Kingdom

#27,714 in the World

Porton Down, United Kingdom

Kalvista Pharmaceuticals Limited

Forward Citations = 99

38 inventors:

Hannah Joy Edwards (16 out of 17 patents)

David Michael Evans (15 out of 25 patents)

Rebecca Louise Davie (13 out of 14 patents)

4. Simon Teanby Hodgson (9 out of 9 patents)

5. David Malcolm Crowe (4 out of 8 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Kalvista Pharmaceuticals Limited. Retrieved from https://idiyas.com/company/kalvista-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…